Bruce Levine: Ten-Year Outcomes Reinforce the Durability of CD19 CAR T-Cell Therapy
oncodaily - Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, shared a post on X: “NEW – Ten-Year Outcomes after CAR T-Cell Therapy for […]
AI Summary: Long‑term data reveal that CD19 CAR‑T therapy produces durable remissions in a subset of B‑cell lymphoma patients, with ten‑year outcomes reinforcing the treatment's long‑term benefit for some. The findings bolster CAR‑T’s curative potential while underscoring the need to identify who will enjoy durable responses.
Related Stories
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 7 days
Teclistamab shows survival benefit prompting earlier use discussions / 21 days
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 2 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 2 months
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 2 months
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 3 months
Romiplostim reduces chemotherapy‑induced thrombocytopenia and prevents recurrence / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, CDC, Zoonotic Disease, Supplements and look for the RSS link.
StackHealth Time Machine